Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors.
Katrina M LappinEliana M BarrosSatpal S JhujhGareth W IrwinHayley McMillanFabio Giuseppe LiberanteCheryl LatimerMelissa J La BonteKenneth Ian MillsD Paul HarkinGrant S StewartKienan I SavagePublished in: Cancer research (2022)
The cancer-associated SF3B1K700E mutation induces DNA damage via generation of genotoxic R-loops and stalled replication forks, defective homologous recombination, and increased replication fork degradation, which can be targeted with PARP inhibitors.